Group 1 - The company is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure related to its periodic reports, which may lead to mandatory delisting if found guilty [1] - The company's stock experienced abnormal trading fluctuations, with a cumulative price deviation of 42.54% over two consecutive trading days [1] - The board of directors confirmed that there are no undisclosed significant matters or changes in the company's operational environment that could affect stock prices [1][3] Group 2 - The controlling shareholder, Hefei Lingcen Technology Consulting Partnership, is facing a court-ordered bankruptcy restructuring, with 32 million shares (4.99% of total shares) set for judicial auction [2][3] - The company has not identified any information that should have been disclosed but was not, and previous disclosures do not require correction or supplementation [3]

Core Viewpoint - The company's stock has experienced a significant price fluctuation, with a cumulative increase of 200% over 30 consecutive trading days, indicating severe abnormal trading activity [1] Group 1: Stock Trading Activity - The company's stock trading has shown a cumulative price deviation of 200% over the last 30 trading days, which is classified as severe abnormal fluctuation according to the Shanghai Stock Exchange trading rules [1] - The company has conducted a self-examination and confirmed with its controlling shareholder that there are no undisclosed significant information apart from what has already been disclosed [1] Group 2: Share Transfer Agreement - The controlling shareholder, SWANCOR, has signed a share transfer agreement with Zhiyuan Hengyue and Zhiyuan Xinchuang Partnership, resulting in the latter two entities collectively holding 29.99% of the company's shares and voting rights [1] - Following the completion of this transaction, Zhiyuan Hengyue will become the new controlling shareholder, with Mr. Deng Taihua as the actual controller [1] Group 3: Approval Process - The transaction is subject to approval by the company's shareholders' meeting and requires compliance confirmation from the Shanghai Stock Exchange, as well as the completion of share transfer registration with the Shanghai branch of the China Securities Depository and Clearing Corporation [1] - There is uncertainty regarding whether the approval process will be successful and the timeline for such approvals [1]

Group 1 - The company's stock experienced an abnormal fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on July 15 and July 16, 2025 [1] - After investigation, the company confirmed that there were no corrections or supplements needed for previously disclosed information [1] - The company did not find any recent media reports that could have significantly impacted the stock price, and its recent operational situation remains normal [1] Group 2 - There have been no significant changes in the internal and external operating environment of the company [1] - The company, its controlling shareholders, and actual controllers have no undisclosed major matters related to the company [1] - There are no major matters currently in the planning stage that require disclosure [1]

中新集团（601512）公告，公司股票于2025年7月14日、7月15日、7月16日连续三个交易日内收盘价格 涨幅偏离值累计超过20%，属于股票交易异常波动情形。经自查及书面问询控股股东及实际控制人，确 认不存在应披露而未披露的重大事项或重要信息。公司目前生产经营活动正常，日常经营情况未发生重 大变化，市场环境、行业政策未发生重大调整。公司股票交易异常波动期间，控股股东及实际控制人、 董事、监事及高级管理人员不存在买卖公司股票的情况。 ...

Core Viewpoint - The company has experienced significant stock price fluctuations, with a cumulative increase of over 20% in two consecutive trading days, indicating potential irrational speculation in the market [1][2][3] Group 1: Financial Performance - For the first quarter of 2025, the company's net profit attributable to shareholders was -42.14 million yuan, and the net profit after deducting non-recurring gains and losses was -43.83 million yuan, both figures unaudited [2][3] - The company's latest price-to-earnings (P/E) ratio is 42.01 times, significantly higher than the industry average static P/E ratio of 7.55 times [2][3] Group 2: Stock Trading Risks - The company's stock has hit the daily limit up for three consecutive trading days as of July 15, 2025, with a notable deviation from the Shanghai Composite Index's growth [1][3] - The company has issued a warning regarding the potential risks associated with secondary market trading, urging investors to make rational decisions [1][3] Group 3: Shareholder and Pledge Risks - The controlling shareholders collectively hold 270,433,332 shares, accounting for 57.02% of the total share capital, with 125,462,357 shares pledged as collateral for convertible bonds, representing 26.45% of the total share capital [3]

Core Viewpoint - The stock price of Wolong New Energy Group Co., Ltd. experienced an abnormal fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from July 10 to July 14, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][4]. Group 1: Financial Performance - For the fiscal year 2024, the company reported a revenue of 361,061.31 million yuan, a year-on-year decrease of 24.08%, and a net profit attributable to shareholders of 4,086.29 million yuan, down 75.15% [2]. - In the first quarter of 2025, the company achieved a revenue of 110,473.79 million yuan, a year-on-year increase of 97.53%, while the net profit attributable to shareholders was 3,608.63 million yuan, reflecting a year-on-year decrease of 22.22% [2]. Group 2: Market Position - As of July 14, 2025, the company's price-to-earnings (P/E) ratio stood at 173.17 times, significantly higher than the industry average P/E ratio of 26.38 times for the "K70 Real Estate" sector [2][9]. Group 3: Operational Status - The company confirmed that its production and operational activities are normal, with no significant changes in the market environment or industry policies, and no major fluctuations in production costs or sales [5]. - There are no undisclosed significant matters that could affect the company's stock price, and no major events have been identified that could impact trading [6][7].

Core Viewpoint - The stock of Saily Medical (603716) has experienced significant trading volatility, with a cumulative price deviation exceeding 20% over three consecutive trading days, indicating abnormal trading activity [3]. Trading Information Summary - On July 11, Saily Medical's stock closed at 25.73 yuan, up 0.47%, with a turnover rate of 33.42%, a trading volume of 638,400 lots, and a total transaction value of 1.595 billion yuan [1]. - The fund flow on the same day showed a net outflow of 70.5244 million yuan from main funds, accounting for 4.42% of the total transaction value, while retail investors had a net inflow of 20.0158 million yuan, representing 1.25% of the total [2][5]. Company Announcement Summary - Saily Medical reported that its stock has been subject to abnormal trading conditions due to a cumulative price deviation exceeding 20% over three trading days. The company confirmed that there are no undisclosed significant matters affecting the stock price, and its operations remain normal [3]. - The company reported a net loss of approximately 209.24 million yuan for 2024, a decrease of 31.95% year-on-year, and an unaudited net loss of about 14.32 million yuan for the first quarter of 2025, a significant decrease of 553.66% year-on-year [3]. - The company’s major shareholder has a high pledge ratio, and the clinical trial application for its joint venture project has been accepted, although the success of the trials remains uncertain [3]. Investor Relations - In response to investor concerns about continuous losses over five years, the company stated that it is implementing various measures to improve operations and performance, including leveraging technology and optimizing financial structures [4].

Core Viewpoint - The stock of Everbright Jiabao Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from July 9 to July 11, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [1][4][6]. Financial Performance - For the fiscal year 2024, the company reported a revenue of CNY 1,817,734,805.35, a decrease of 58.59% compared to the previous year. The net profit attributable to shareholders was -CNY 1,394,338,884.70, and the net profit after deducting non-recurring gains and losses was -CNY 1,511,103,796.23 [2][6]. - In the first quarter of 2025, the company achieved a revenue of CNY 310,713,649.40, down 9.05% year-on-year, with a net profit of -CNY 118,220,254.22 and a net profit after deducting non-recurring gains and losses of -CNY 124,695,272.81 [2][6]. Shareholder Actions - The company disclosed a share reduction plan by its major shareholders, Shanghai Jiading Jianye Investment Development Co., Ltd. and its concerted party, Shanghai Jiading Technology Investment (Group) Co., Ltd., intending to reduce their holdings by up to 14,996,854 shares, not exceeding 1% of the total share capital, within three months after the announcement [3][6]. Market Position - As of July 11, 2025, the company's price-to-book ratio was 1.62, which is higher than the industry average of 0.82 for the "K70 Real Estate" sector [2][5][6]. Operational Status - The company confirmed that its production and operational order remains normal, with no significant changes in the internal and external operating environment [4][5].

Core Viewpoint - The company, Tianmao Industrial Group Co., Ltd., is facing regulatory scrutiny due to failure to timely disclose financial reports, leading to a risk of delisting from the Shenzhen Stock Exchange [1][2]. Group 1: Stock Trading and Regulatory Actions - The company's stock experienced abnormal trading fluctuations, with a cumulative closing price drop exceeding 12% over three consecutive trading days from July 8 to July 10, 2025 [2]. - The China Securities Regulatory Commission (CSRC) issued a notice of investigation on May 6, 2025, due to the company's failure to disclose periodic reports as required by law [1][2]. - Following the investigation, the company was suspended from trading for two months starting May 6, 2025, and resumed trading on July 8, 2025, under a delisting risk warning [1][2]. Group 2: Disclosure and Corporate Governance - The company's board confirmed that aside from the delayed disclosure of the 2024 annual report and the 2025 first-quarter report, there are no other undisclosed significant matters that should be reported according to the Shenzhen Stock Exchange's regulations [2]. - The board has not been made aware of any other information that could significantly impact the trading price of the company's stock or its derivatives that has not been disclosed [2].

Core Viewpoint - Shandong Weiming Pharmaceutical Co., Ltd. faces significant operational challenges due to the suspension of production and sales at its subsidiary Tianjin Weiming Biopharmaceutical Co., Ltd., leading to a risk warning for its stock and a change in trading status to "ST Weiming" [1][3]. Group 1: Stock Trading and Risk Warnings - Tianjin Weiming was subjected to risk control measures on April 22, 2025, and is expected to be unable to resume normal operations within three months as of July 4, 2025, triggering a risk warning under the Shenzhen Stock Exchange regulations [1][3]. - The company's stock price experienced a cumulative decline of 15.82% over three consecutive trading days starting July 8, 2025, indicating abnormal trading fluctuations [1][2]. Group 2: Financial Impact and Company Performance - In 2024, Tianjin Weiming generated revenue of RMB 216.57 million and incurred a net loss of RMB 14.00 million, accounting for 60.09% of the company's total revenue and 9.8% of the consolidated net profit [2]. - For the fiscal year 2024, the company reported total revenue of RMB 360.41 million and a net loss attributable to shareholders of RMB 137.31 million, with the first quarter of 2025 showing revenue of RMB 35.33 million and a continued net loss [3].